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Abstract 
Background: Pain is associated with shorter survival in non-small cell lung cancer (NSCLC). 
Lung cancer cells express opioid receptors. Opioids promote angiogenesis, tumor growth and 
metastases, and shorten survival in animal models.  
Methods: To examine if long-term opioid requirement, independently of chronic pain, is 
associated with survival, we studied 209 patients treated with chemotherapy for stage IIIB/IV 
NSCLC. Pain was stratified by proportion of time patients reported specific levels of pain. 
Opioids were converted to oral morphine equivalents (OME) for comparison. The effects of pain, 
opioid requirement, and known prognostic variables on survival were analyzed in univariable and 
multivariable models.  
Results:  Both severity of pain and greater opioid requirement in first 90 days after starting 
chemotherapy were strongly predictive of shorter survival on univariable analysis. Patients with 
no/mild chronic pain and requiring <5 mg/day OME during first 90 days had nearly 12 months 
longer median survival compared to patients requiring ≥5 mg/day OME and/or experiencing more 
pain. Differences in survival remained remarkably similar when chronic pain and opioid 
requirement were assessed over the entire clinical course (until death or last follow-up). In 
multivariable models, both opioid requirement and chronic pain remained independent predictors 
of survival, after adjustment for age, stage and performance status. 
Conclusions: Severity of chronic cancer-related pain or greater opioid requirement are associated 
with shorter survival in advanced NSCLC, independently of known prognostic factors. While 
pain adversely influences prognosis, controlling it with opioids does not improve survival. 
Prospective studies should determine if achieving pain control using opioid-sparing approaches 
improves outcomes.
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Introduction 
Cancer related pain is common, negatively impacts quality of life, and often requires opioid 
analgesics. Two-thirds of patients with advanced malignancies experience pain, with almost 50% 
experiencing moderate-severe pain.[1] Opioid medications are the mainstay of treatment of 
severe, chronic cancer pain.[2, 3] Experimental studies and retrospective clinical analyses raise 
the concern that opioids might promote cancer progression and reduce survival.[4-18] 
The role of the mu-opioid receptor 
Morphine and other opioids are the 
mainstays of pain management in cancer 
patients.[2] Opioids exert their analgesic 
effects through opioid receptors. The mu-
opioid receptor (MOP-R) is one of 4 major 
opioid receptors. MOP-R expression has 
been demonstrated in cancers of the breast, 
lung, prostate, colon, and esophagus.[4, 18-
20] There is a complex interplay among 
cancer pain, exogenous opioids (eg, 
morphine), endogenous opioids (eg, beta-
endorphins), MOP-R, and cancer growth and 
progression (Figure i).[21]  
Clinical studies of opioids, cancer progression and the mu-opioid receptor 
Clinical studies also suggest that MOP-R and opioid exposure are associated with inferior 
survival in patients with advanced malignancies.[18, 22-24] We have reported that the level of 
 
Figure i. Overview of cancer pain, opioids, the 
mu opioid receptor, and cancer progression 
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MOP-R expression in samples from patients with prostate cancer was independently associated 
with worse OS.[18] Others have shown that blocking MOP-R with methylnaltrexone is associated 
with lower rates of tumor progression in patients with advanced cancers.[25] In addition, genetic 
polymorphisms in MOP-R have been associated with both increased breast cancer development 
and decreased breast cancer-specific survival.[22, 26]   
In a retrospective study of patients with advanced prostate cancer receiving androgen deprivation 
therapy, we found that greater opioid requirement and higher levels of MOP-R expression in the 
tumor specimen are independently associated with shorter progression-free survival (PFS) and 
overall survival (OS).[18]  
Because high MOP-R expression was associated with shorter OS, we conducted a subset analysis 
in prostate cancer patients with high MOP-R, stratified on opioid exposure (n=36 total patients, 
unpublished findings). Of patients with high MOP-R, those with LOE (n=13) had longer OS than 
those with HOE (n=23) (median OS, 503 vs. 387 days, P=0.05, Figure ii.).  
 
 
 
 
 
 
 
Figure ii. Kaplan-Meier curves for overall survival in 
patients with hormone-sensitive metastatic prostate 
cancer with high mu opioid receptor expression based on 
opioid exposure (N=36). 
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These data suggest that high baseline MOP-R levels alone may have a negative affect (because 
endogenous opioids alone may induce MOP-R’s growth-promoting properties) and that patients 
using high amounts of exogenous opioids may have shorter OS due to excessive MOP-R 
activation. These data indicate that baseline MOP-R expression may strongly predict both 
response and long-term survival, independent of other key factors. This is consistent with 
laboratory and animal evidence suggesting an association of MOP-R expression, opioids, and 
cancer progression. These findings require confirmation in other tissue samples from patients 
with other advanced cancers. If results are consistent, it would warrant larger clinical trials to 
further assess the effect on treatment. 
More recently, Halabi et al. confirmed and extended our findings to patients with advanced 
prostate cancer receiving first-line chemotherapy, reporting that opioid use is an independent 
prognostic factor for survival.[27] Some prospective studies suggest that systemic exposure to 
endogenous or pharmacological opioids may promote cancer progression in patients with 
astrocytomas,[28] pancreatic cancer[29] and various advanced solid tumors including lung 
cancer.[30]. 
The role of pain and opioids in lung cancer 
Pain at diagnosis is itself associated with shorter survival in lung cancer[31, 32] and other 
malignancies.[27, 33-38] Pain may induce cancer progression via tumor innervation[39] and 
release of tachykinins such as substance P,[40] endogenous opioid peptides that modulate 
immune function,[41] or cyclo-oxygenase-mediated release of prostaglandins.[42, 43] Therefore, 
it is not clear whether reduced survival in patients treated with opioids is due to opioids and/or 
pain. Since pain has a direct impact on the quality of life and perhaps disease outcomes, it is 
critical to understand the independent contribution of pain and opioids to cancer progression and 
survival, to develop appropriate strategies to improve outcomes in patients with malignancies. 
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Lung cancer is the most common malignancy worldwide,[44] and ranks third highest for pain 
prevalence out of all malignancies.[1]. Pre-clinical data on cellular mechanisms and murine 
models demonstrate that opioids promote lung cancer progression and metastasis and reduce 
survival.[5, 6, 14, 16] Opioids via MOP-R directly activate mitogenic signaling and also by co-
activating receptor tyrosine kinases (RTKs) including vascular endothelial growth factor receptor-
2 (VEGFR2) and epidermal growth factor receptor (EGFR) in endothelial[4] and lung cancer 
cells.[5, 6, 14, 16] respectively, and epithelial-mesenchymal transition.[16] MOP-R expression is 
increased in several different human lung cancer tissues as compared to normal human lungs.[5, 
45] These findings suggest the possibility that opioids may be associated with lung cancer 
progression in patients. 
Rationale for current study 
The above studies did not differentiate between the impact of pain and opioid use independently 
of the other. These previous studies also did not evaluate the effect of chronic (ongoing) pain or 
long-term quantitative opioid exposure on cancer outcomes. Furthermore, there is marked inter-
patient variability in treatment of pain and use of opioids, depending upon individual patients’ 
pain thresholds and patient and provider pain management preferences.[2, 3] Therefore, in this 
retrospective analysis, we objectively determined the effect of chronic cancer-related pain and 
quantitative systemic opioid use, independent of each other, on survival of patients with advanced 
NSCLC. 
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Methods 
 
Patients 
We analyzed data on 209 patients diagnosed with stage IIIB/IV non-small cell lung cancer from 
2003-2010 at the Minneapolis Veterans Affairs (VA) Health Care System (MVAHCS) who were 
treated with palliative chemotherapy, to determine whether pain or opioid requirement is 
associated with survival. Demographic, clinical, and pharmacy data were obtained from patient 
records, the tumor registry, and VA Data Support Services. The study was approved by the 
institutional Human Subjects Committee. 
Opioid Requirement 
All oral and transdermal outpatient opioid prescriptions dispensed from any VA in the USA from 
2002-2012 were collected to determine the total opioid quantity dispensed per prescription. All 
opioid prescriptions were converted to oral morphine equivalents (OME) using an equi-analgesic 
conversion table, as previously described.[18] Average daily opioid requirement was calculated 
for three distinct treatment intervals: 1) 90 days prior to chemotherapy initiation, 2) 90 days after 
chemotherapy initiation, and 3) chemotherapy initiation to death/last follow up.  
Pain Levels 
All pain values recorded from both inpatient and outpatient clinical encounters were collected on 
each patient. As with opioid requirement, pain levels were analyzed for each of the three 
treatment intervals (i.e., 90 days before chemotherapy, 90 days after starting chemotherapy, and 
from chemotherapy to death/last follow up). Severity of pain was categorized in accordance with 
the Brief Pain Inventory: low pain (pain levels 0-3), moderate pain (pain levels 4-6), and severe 
pain (pain levels 7-10).[46] For analysis of pain during the 90 days before chemotherapy, we used 
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the patient’s maximum reported pain level (≥ 7 vs < 7) in order to maintain consistency and 
comparability with reported studies. 
Pain-Opioid Groups 
For treatment intervals after chemotherapy initiation, both pain and opioid requirement were 
separated into high and low groups to better assess for interactions (Table i.).  
Table i. Categorization of pain levels and opioid requirement 
 
Pain was stratified by the proportion of time a patient reported severe pain (high pain [HP] group: 
≥ 10% of all recordings, low pain [LP] group: < 10% of all recordings), or moderate-severe pain 
(HP group: ≥ 25% of all recordings, LP group: <25% of all recordings). Patients requiring ≥ 5 
mg/day OME (the equivalent of the lowest single immediate-release tablet strength for morphine) 
were considered to have high use (thus, high opioid [HO] group: ≥ 5 mg/day OME, low opioid 
[LO] group: < 5 mg/day OME).   
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Four subgroups were created based on severity of pain and quantitative opioid requirement, 
reflecting the different clinical scenarios observed in clinical practice:[2, 3] (a) low pain/low 
opioid (LPLO), b) low pain/high opioid (LPHO), c) high pain/low opioid (HPLO), and d) high 
pain/high opioid (HPHO). The LPLO (reference) group included patients experiencing minimal 
pain and requiring no/minimal opioids. The LPHO group included patients with good pain control 
with high opioid utilization; the HPLO group comprised of patients experiencing higher levels of 
pain but no/minimal opioid utilization (perhaps due to patient preference or intolerability to 
opioids, or prescribing practices: a phenomenon well-recognized in the literature[2, 3]). The 
HPHO group included patients experiencing higher levels of pain despite higher opioid use. This 
grouping thus aimed to separate patients with chronic severe pain alone (HPLO) from those with 
higher opioid exposure alone (LPHO) from the reference group with neither of these factors 
(LPLO). 
Statistical analysis 
Cox proportional-hazards regression models were used to compare the subgroups for OS. The 
effects of individual factors on OS were evaluated using Kaplan-Meier analyses. For 
multivariable cox models, OS was analyzed after adjusting for known prognostic factors at time 
of diagnosis (age, performance status and stage of disease). Indicator variable coding was used to 
compare pain-opioid subgroups (LPLO, HPLO, LPHO, HPHO), with the LPLO serving as the 
reference group against which the other three groups were compared.  
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Results 
Patient demographics 
As shown in Table ii., the majority of patients were male (98%), had stage IV disease (71%), and 
had good performance status (75% had ECOG PS of 0-1). Nearly half had experienced severe 
pain (i.e., at least one pain level of 7 or higher) in the 90 days preceding chemotherapy, with a 
similar proportion receiving opioids prior to chemotherapy. These percentages show the 
population to be relatively high functioning with advanced disease, yet also balanced in regards to 
baseline pain and opioid requirement. The predominantly male VA population precludes 
generalization of our results to female patients.  
 
 
 
 
 
 
 
 
 
Table ii. Baseline characteristics 
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Association of pain level and opioid requirement with survival 
We first examined in univariable models whether pain level or opioid requirement at different 
time periods during the course of the disease were associated with survival (Table iii.).  
The presence of chronic severe pain, moderate-severe pain, or high opioid requirement in the first 
90 days after initiation of chemotherapy, or during the entire treatment period (chemotherapy 
initiation to death/last follow up), was significantly associated with shorter OS. However, while 
patients experiencing a maximum pain level of 7 or higher prior to initiation of chemotherapy had 
shorter survival, greater opioid requirement prior to initiation of chemotherapy was not associated 
with survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table iii. Association of chronic pain and opioid requirements with overall survival 
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Determination of the individual effects of pain level and opioid requirement on survival 
We next attempted to differentiate the individual associations of pain and opioids with survival, 
using the pain/opioid groupings (LPLO [reference group], HPLO, LPHO and HPHO) described 
in the Methods. Analyses were performed for two time intervals in the clinical course (first 90 
days after chemotherapy initiation, and chemotherapy initiation to death/last follow up) and for 
two pain stratifications (severe pain and moderate-severe pain). The probabilities of survival in 
each of these groups were estimated using Kaplan-Meier analyses (Fig. iii).   
Association of pain and opioid requirement in the first 90 days after chemotherapy initiation with 
survival 
Survival of patients in the LPLO (reference) group was significantly longer compared to the 
HPLO, LPHO, and HPHO groups (median survival,17.9 months vs. 5.7, 6.5, and 6.1 months, 
respectively, log-rank p value=0.002) stratified on the presence of severe pain (Fig. iiiA). 
Similarly, markedly different survivals were observed between the LPLO group and the other 3 
groups when patients were stratified on the presence of moderate-severe pain (17.9 months vs. 
5.7, 7.7, and 4.2 months, respectively, log-rank p-value=0.001; Fig. iiiB). These findings suggest 
that higher levels of pain and/or greater opioid requirement early in the treatment period are 
predictive of shorter survival in patients with advanced NSCLC. 
Association of pain and opioid requirement during the entire clinical course with survival 
Remarkably similar differences in survival were observed between the reference LPLO group and 
the other 3 groups when pain level and opioid requirement were assessed from chemotherapy 
initiation to death/last follow up. Median survival in the LPLO group was significantly longer 
compared to the HPLO, LPHO, and HPHO groups (16.0 months vs. 5.5, 6.5, and 7.8 months, 
respectively, log-rank p-value<0.001), stratified by severe pain (Fig. iiiC). Again, similar survival 
differences were seen using the moderate-severe pain stratification for this treatment interval 
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(16.4 months vs. 6.4, 7.1, and 7.7 months, respectively, log-rank p-value=<0.001) (Fig. iiiD). 
These findings indicate that the presence of chronic pain or high opioid requirement are 
associated with markedly shorter survival in patients with advanced NSCLC.  Patients 
experiencing little to no pain and also consuming less than 5 mg oral morphine/day have 
considerably longer survival. 
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Figure iii. Overall survival based on pain and opioid requirement 
Figure legend. The overall survival of patients experiencing different levels of chronic pain and requiring 
varying amounts of opioids (defined as described in the Methods and Table i) was estimated using the 
Kaplan-Meier method. The presence of higher levels of pain, greater opioid requirement, or both, was 
strongly associated with shorter survival. Significance of differences between the groups are provided in 
the Results section. 
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Multivariable analyses of pain, opioids and known prognostic factors 
Finally, we evaluated if chronic pain level and/or opioid requirement are associated with 
differences in survival when clinical prognostic variables (age, performance status and stage of 
disease) are included in multivariable Cox regression analyses (Table iv.).  
Table iv. Independent associations of chronic pain and opioid requirements with overall survival in 
multivariable models including known prognostic factors 
 
 
Longer survival of patients in the LPLO reference group remained significant for both pain 
classifications (severe pain or moderate-severe pain) and both treatment intervals (first 90 days 
after chemotherapy initiation or chemotherapy initiation to death/last follow up). In all these 
analyses, age, performance status and stage also remained significantly associated with survival, 
confirming the validity of the data set and outcomes. Of particular relevance, these results 
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indicate that chronic pain and/or higher opioid requirement in the first 3 months of treatment are 
individually and independently predictive of shorter survival in patients with advanced NSCLC. 
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Discussion 
Quality of life and survival are influenced by pain and its treatment in cancer patients. However, 
it is not known if pain and analgesics influence these outcomes independent of one another or if 
their effect is inter-dependent. We show here for the first time that the presence of either chronic 
severe pain or greater quantitative opioid requirement is associated with markedly shorter 
survival in patients with advanced NSCLC, independent of known clinical prognostic factors. 
The independent impact of chronic pain on clinical outcomes can be difficult to discern because it 
is often incorporated into different quality of life (QOL) assessment instruments that generate 
global QOL scores. To specifically examine the influence of chronic pain by itself on survival, 
we took advantage of the VA’s electronic databases that document every pain level reported by 
inpatients and outpatients over the entire course of their disease; these databases provide a 
comprehensive assessment since patients in the VA system are rarely lost to follow up or go 
elsewhere for treatment. To minimize the disproportionate impact of single pain levels (which can 
fluctuate widely), we categorized patients with respect to the severity of chronic pain by 
calculating the proportion of times a patient reported pain above certain levels on a 0-10 scale 
over a longer period of time. This approach also allowed us to incorporate into our analyses all 
pain levels from any clinical encounter a patient had in the VA system.  
Prior reports have separately shown that pain and opioid requirement are prognostic factors for 
OS in various malignancies,[18, 27, 31] but none of these studies simultaneously examined the 
individual or combined effects of both these inter-related factors. Segregating the severity of pain 
from opioid utilization poses a major challenge in such analyses. We were able to identify 
subgroups of patients experiencing higher levels of pain but not exposed to much opioids (the 
HPLO group), those experiencing little or no chronic pain but exposed to larger quantities of 
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opioids (the LPHO group), and those experiencing greater pain and exposed to higher amounts of 
opioids (HPHO group).[2, 3] Comparing these groups with a reference group of patients without 
much pain or opioid exposure (the LPLO group) allowed exploration of the potential impact of 
pain alone (HPLO group), opioids alone (LPHO group) or both factors on clinical outcomes. This 
strategy was able to identify highly significant and independent associations of pain and opioid 
requirement on overall survival, and may provide a useful method to evaluate the influence of 
these inter-related factors in other malignancies. 
These clinical data complement earlier studies from our laboratory showing that chronic opioid 
administration leads to increased cancer progression and metastasis and reduced survival in mice 
with breast cancer.[7, 17] Hyperalgesia continued to increase in both control and morphine 
treated mice over time, but co-treatment with morphine and celecoxib (a COX-2 inhibitor) 
reduced hyperalgesia as well as cancer progression and metastasis and survival in these mice, 
suggesting that pain is associated with cancer progression and survival.[7] Opioid-induced 
hyperalgesia (OIH) may amplify existing pain, and may be an additional factor contributing to 
inferior outcomes in cancer. Thus, the present clinical observations together with earlier murine 
cancer studies demonstrate that pain may critically influence survival, independent of opioid use. 
Recent studies in humans support the hypothesis generated by pre-clinical studies that stimulation 
of opioid receptor signaling promotes cancer progression, which in turn may also influence 
survival. Madar et al. showed using positron emission tomography that human lung cancers 
express higher levels of mu opioid receptors in vivo compared to adjacent normal lung tissue; 
binding of ligands (and thus likely also opioid medications and endogenous opioids) was 
effectively blocked by opioid antagonists in the tumor tissue in vivo.[45] These findings suggest 
that it may be possible to block the potential adverse effects of opioid receptor signaling in 
cancers. The need to examine the possible benefit of such strategies is underscored by our 
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observation in men with metastatic prostate cancer that both increased MOP-R expression and 
greater opioid requirement are independently associated with shorter progression-free and overall 
survival.[18] 
Pain at diagnosis of lung cancer has been cited as a prognostic factor in patients with metastatic 
NSCLC. In a comprehensive literature search of pain in patients with stage IIIB/IV NSCLC, we 
found that pain at diagnosis was significantly associated with shorter survival on univariable 
analyses in approximately 80% of studies (unpublished results). Pain remained significant when 
clinical variables including age, gender, performance status, and stage of disease were included in 
multivariable analyses in some studies.[31, 32] However, none of these studies assessed the 
impact of chronic (long-term) pain, opioid requirement or MOP-R expression on outcomes. 
Consistent with these previous reports, we observed that the level of pain at diagnosis was 
significantly associated with survival. However, given the subjective and highly variable nature 
of pain, determination of a single pain level at diagnosis cannot reliably reflect the intensity (or 
influence) of chronic pain experienced by patients with advanced malignancies. 
The poor survival of patients in the LPLO group may be related to the adverse effects of opioids. 
Alternatively, it is possible that pathways activated by pain[39-43] continue to exert their 
detrimental effects in advanced malignancies even after the perception of pain is relieved by 
opioid analgesics. Further investigation is required to distinguish between these possibilities. 
Of note, the current study analyzed the association of chronic pain (from diagnosis till death) and 
quantitative, long-term opioid requirement with survival in patients with advanced cancer. 
Several retrospective[47-51] and one prospective[52] studies have examined the association of 
recurrence/survival with anesthetic technique and/or short-term peri-operative opioid 
administration in patients operated for early stage malignancies. However, the pharmacological 
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effects of opioids, immune function, opioid receptor expression and activity are likely quite 
different in the two settings.   
Measuring the predictors (pain level and opioid requirement) concurrently with the outcome 
(survival) up till the time of death can introduce statistical bias. We therefore also analyzed the 
association of the predictors (pain and opioids) restricted to the first 90 days of chemotherapy 
(during which few patients died), with subsequent survival. Restricting analysis to the first 90 
days after chemotherapy initiation also helped reduce the disproportionate impact of increasing 
pain and opioid requirement as patients approached the end of life (i.e., hospice care). In addition 
to avoiding statistical bias, our findings with this approach indicate that the severity of pain and 
quantitative opioid requirement early in the clinical course of advanced NSCLC are strongly and 
independently predictive of survival. Demonstrating significant and remarkably comparable 
associations with both pain predictors (severe pain or moderate-severe pain) and both analysis 
intervals (from initiation of chemotherapy to day 90, or from initiation of chemotherapy to 
death/last follow-up), further strengthens the validity of our findings.  
The limitations of this study are that 1) it is retrospective, 2) opioid prescriptions dispensed were 
used as a measure of actual opioid consumption, 3) the confounding effect of tumor location and 
extent on pain levels, opioid requirements and outcomes could not be entirely excluded, and 4) it 
included the various histologies that are grouped under non-small cell lung cancer. 
In conclusion, we report that patients with advanced non-small cell lung cancer experiencing 
more severe chronic cancer-related pain or having greater long-term opioid requirement are more 
likely to experience shorter survival, independently of the influence of known prognostic factors. 
Importantly, while pain is an independent prognostic factor, controlling it with opioid 
medications does not improve outcomes. Prospective investigations are warranted to determine if 
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managing pain with opioid-sparing approaches improves survival in patients with advanced 
malignancies. Until results of such studies are available, clinical practice aimed at relieving 
cancer pain should not be changed. 
  20 
Future Directions 
There is an urgent need for clinical translation of the in vitro, animal, and retrospective clinical 
data that suggest a negative effect of opioids on overall cancer survival. Given the high 
prevalence of cancer pain and corresponding use of opioids, any notion of opioids being “bad” 
may have dramatic repercussions for patients, providers, and policy-makers. While much is 
written about the management of cancer pain, few studies address how control of pain may affect 
clinical outcomes. MOP-R has an important role in cancer progression that is well defined with in 
vitro and in vivo studies, yet few have studied MOP-R expression, pain, and opioid use in 
patients with cancer. As such, I have expanded on the work in this thesis project with a number of 
research projects to help answer these important questions. These projects are summarized briefly 
below.  
Impact of opioid use on health care utilization and survival in patients with newly diagnosed 
stage IV malignancies 
Patients with advanced cancers frequently experience pain. Opioids are commonly prescribed to 
treat cancer-related pain, but their use might be associated with undesirable consequences 
including adverse effects and tumor progression, which may result in increased heath care 
utilization and shorter survival. We examined this possibility in a large cohort of patients 
diagnosed with ten common types of advanced malignancies. 
We identified 1,386 patients with newly diagnosed stage IV non-hematologic malignancies from 
2005-2013 and ascertained opioid utilization within 90 days of starting anti-cancer treatment 
using data from electronic health medical records and our tumor registry. Opioid utilization was 
stratified into low opioid (LO; < 5mg oral morphine equivalents (OME)/day) and high opioid 
(HO; ≥5 mg OME/day). Health care utilization included tallies of all emergency room, urgent 
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care, and inpatient visits. The association of opioid use, prognosis of tumor type, age, and gender 
with overall survival was analyzed in univariate and multivariate models.  
HO use patients (n=624) had greater health care utilization at 3, 6, and 12 months after diagnosis 
compared to LO use patients (n=762; p <0.05). HO use patients also had shorter survival 
compared to LO use patients (median survival, 5.5 vs 12.4 months; p < 0.0001). On multivariate 
analysis, HO use remained associated with shorter overall survival (HR 1.4; 95% CI, 1.3- 1.6; 
p<0.0001) after adjusting for age, gender and prognostic group (cancer type).  
In patients with advanced cancer, HO use is associated with greater health care utilization and 
shorter survival. Prospective studies using opioid-sparing approaches are indicated, to confirm 
these retrospective findings and to evaluate if these undesirable effects associated with opioid use 
can be mitigated. 
Mu-opioid receptor levels, opioid exposure, and survival in patients with stage IV pancreatic 
cancer 
The purpose of this project is to: 1) measure MOP-R levels in human pancreatic cancer cells from 
a stored diagnostic biopsy sample; 2) determine the association between the level of MOP-R and 
OS of patients with pancreatic cancer; and 3) determine the joint relationship between MOP-R 
levels and opioid exposure on OS in this cohort.      
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Figure iii., the conceptual model for our proposal, is based on our OS estimates from the 
literature and our experience. We believe that those with high MOP-R expression and HOE will 
have inferior survival, especially compared with those with low MOP-R expression and LOE. 
Our proposal will allow determination of MOP-R expression of stored biopsies from patients with 
stage IV pancreatic cancer for whom mortality and opioid exposure data is available in the EHR. 
The goal is to determine if MOP-R expression and opioid exposure affected the OS. Tumor cell 
blocks from original biopsies will be used to address the relevance of this biological marker in 
determining best practices for pain management and OS in pancreatic cancer patients. 
 
 
 
 
 
This is a retrospective study to quantify MOP-R levels in stored biopsies from deceased 
pancreatic cancer patients who presented with stage IV pancreatic cancer from 2005 to 2015 to 
the Health Partners Park Nicollet Frauenshuh Cancer Center, Minneapolis, MN. Data sources 
include stored biopsy tissue samples that will be analyzed for MOP-R expression and the EHR 
data warehouse for demographic, clinical, opioid exposure, and mortality data.  
Using the EHRs at Frauenshuh Cancer Center, we have identified 90 deceased patients with stage 
IV pancreatic cancer diagnosed from 2005 to 2015. To be eligible for inclusion, patients needed 
pathology reports indicating a core needle biopsy of >0.5 cm in total length (fine needle 
aspiration or cytology were excluded because MOP-R analysis cannot accurately be ascertained 
 Figure iv. Conceptual model for MOP-R effects. 
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on these specimens) and needed adequate opioid use data during the first 90 days after 
chemotherapy initiation. The study pathologist will review the 90 diagnostic pathology reports 
from the pancreatic cancer patients identified for this project. The pathologist will locate and 
examine the paraffin blocks and slides of diagnostic tumor tissue obtained from core biopsies of 
metastatic sites to be used for the MOP-R testing to ensure that blocks have adequate tumor cells 
for analysis. From these 90 patients, we estimate that we will have at least 60 viable samples.   
A Phase II Trial of Naloxegol in Metastatic Pancreatic Cancer Patients  
We have submitted a proposal to conduct a prospective, single-arm study to assess the effects of a 
16-week treatment with naloxegol in patients with metastatic pancreatic cancer.  Naloxegol is a 
peripherally-selective opioid antagonist for the treatment of opioid-induced constipation. It was 
approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe 
and well tolerated for 52 weeks. When given concomitantly with opioid analgesics, naloxegol 
reduced constipation-related side effects, while maintaining comparable levels of analgesia. We 
posit that early, ongoing use of naloxegol in patients with metastatic pancreatic cancer will not 
only provide optimal management of patient side effects (e.g., constipation) related to peripheral 
activation of mu receptor by opioids, but also will decrease angiogenic stimulus in tumor tissue, 
thereby reducing rate of tumor growth and metastases.  
Patients with newly diagnosed (de-novo or recurrent) metastatic pancreatic ductal 
adenocarcinoma (PDAC) will be invited to join this study prior to initiation of standard therapy 
with gemcitabine and nab-paclitaxel [53].  Patients will be treated with 16 weeks of naloxegol 
along with gemcitabine and nab-paclitaxel and stratified by high or low mu-opioid receptor 
status.  The primary endpoint will be assessment of Ca 19-9 levels. 
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A Randomized Trial of Medical Cannabis in Patients with Newly Diagnosed, Stage IV Lung and 
Pancreatic Cancers to Assess Impact on Cancer-Related Symptoms: A Pilot and Feasibility Study 
Medical cannabis has been available in the state of Minnesota since July 2015, and has the 
potential to improve cancer related pain, chemotherapy-induced nausea and vomiting, along with 
other symptoms. In the first 15 months of the program, only 492 patients throughout the state of 
Minnesota received medical cannabis for cancer related symptoms. The overall safety profile of 
medical cannabis is still being explored, but serious adverse events in the Minnesota program 
appear rare. However, three factors severely limit use of medical cannabis in the cancer 
population; 1) the lack of rigorous scientific data demonstrating improvement in symptoms 
compared to usual care, 2) concerns from patients and clinicians on side effects, impact on 
current oncology treatments, and potential legal ramifications, and 3) a monthly cost to patients of 
approximately $300. 
I am leading a workgroup with our Park Nicollet/HealthPartners research team, the Minnesota 
Department of Health, and leadership from both registered medical cannabis manufacturers in the 
state; LeafLine Labs and Minnesota Medical Solutions. The goal of our workgroup is to 
spearhead innovative research studies with medical cannabis as a focus. We have drafted a 
protocol for a randomized, observational study of medical cannabis use in patients with stage IV 
lung and pancreatic cancers to collect pilot data and support an NIH grant for a larger state-wide 
clinical trial through the Metro-Minnesota Community Oncology Research Consortium 
(MMCORC). We are seeking funding for this pilot study at Park Nicollet Frauenshuh Cancer 
Center (FRCC) and HealthPartners Regions Cancer Center (RCC) to determine feasibility and 
provide important pilot data for larger grant funding. 
In collaboration with LeafLine Labs, Minnesota Medical Solutions, and the Minnesota 
Department of Health and the Office of Medical Cannabis, we will conduct a randomized clinical 
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trial to assess how early implementation of medical cannabis impacts cancer-pain, symptom 
management, and opioid utilization. The feasibility of recruiting/enrolling patients across 
institutions, conducting the study per protocol, and achieving good long-term follow-up will be a 
key aim in order to show this study can be expanded through MMCORC. Oncology patients with 
newly diagnosed, stage 4, lung and pancreas cancers meeting criteria for certification in the 
Minnesota’s Medical Cannabis Program for the severe/chronic pain indication will be offered 
participation in study. Patients will be randomized 1:1 to early cannabis (EC) (n=25) vs delayed 
cannabis (DC) (n=25). The EC group will be provided with 3 months of medical cannabis at no 
charge. The DC group will receive usual care for the first 3 months, and then be provided 3 
months of medical cannabis at no charge after 3 months. All patients will be required to complete 
a validated quality of life instrument (Patient-Reported Symptom Monitoring (PRSM)) every 28 
days while in the study. The PRSM is a 23 question tool for oncology patients that addresses 
common symptoms (e.g., pain, nausea, fatigue, and depression), patient-assessed performance 
status, and overall quality of life.  
Implementation of Electronic Patient-Reported Symptoms in Cancer Patients 
We received grant funding to conduct a pilot project to build, test and evaluate uptake of an 
electronic Patient Reported Outcomes (ePROs) system to collect and track symptoms for 
oncology patients.  Public and private investment and widespread adoption of the electronic 
health record (EHR) affords us the opportunity to incorporate the patient’s voice and perspective 
on their symptoms directly into the EHR using the patient portal, MyChart.   This project is 
applicable across our entire HealthPartners organization and nationally in other health care 
delivery systems. It will inform and extend our capacity for building electronic patient- reported 
outcomes, which is an organizational priority.  The proposed system will deliver a validated 
symptom survey consisting of 23 questions and an internally generated pilot form consisting of 7 
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questions regarding the patient’s individual pain goal and pain medication use.  Both surveys will 
be delivered to consented study participants using EPIC MyChart.  These data will then be 
directly integrated into our current EHR and will 1) generate symptom summary sheets that are 
available at point of care to patients and physicians and 2) be incorporated into a symptom 
flowsheet (discreet data points on each symptom) that will allow longitudinal follow up on each 
reported symptom.  Successful completion of this pilot will allow us to extend the ePRO system 
to more of our oncology patient population as part of our standard of care and serve as a model 
for other HP departments. This system will allow patients, clinicians and researchers to capture, 
describe and manage complex symptoms and more fully incorporate the patient experience in 
symptom-generated clinical care protocols. 
Patients with metastatic cancer have a high symptom burden. Symptom control measures, 
especially for pain, are highly correlated with overall patient satisfaction and survival. However, 
studies show clinicians often underestimate the symptom burden of their patients. One reason for 
this is that clinicians meet with patients at the start of chemotherapy cycles when symptoms from 
the previous treatment cycle have often improved.  Yet, patient-reported symptoms, when 
efficiently collected and integrated into the EHR, can help care providers and patients make 
clinical decisions that have a positive impact on patient well-being. 
Objective: To demonstrate the feasibility of building and implementing an ePRO system that will 
capture and extract patient-reported outcomes electronically using the integrated patient portal of 
our EHR (MyChart) for patients with stage IV cancer. 
Specific Aims: 
(1) To develop, test and evaluate an electronic data capture system that will collect electronic 
patient- reported outcomes( ePROS) using MyChart, the patient portal function of our EHR 
(EPIC) 
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(2) To build and extract a summary report of the ePRO from EPIC that is available at point 
of care to patients and providers 
(3) To incorporate ePROs responses directly into EPIC flowsheet with discreet data fields 
that provides longitudinal data 
In order to accomplish these aims, patients with stage IV non-hematologic cancers will be invited 
to consent to join this pilot study. We will develop and implement an ePRO system using the 
EPIC MyChart survey platform to administer the Patient-Reported Symptom Monitoring (PRSM) 
tool (University of North Carolina). The PRSM is a validated 23 question ePRO tool for 
oncology patients that addresses common symptoms (e.g., pain, nausea, fatigue, and depression), 
patient-assessed performance status, and overall quality of life. We will also continue to pilot an 
internally developed questionnaire regarding the individual Personalized Pain Goal and 
Medication Use (PGMU).  Patients will complete the surveys every 14 days (+/- 2 days) via 
MyChart online. 
Alternative methods of survey completion will be available, if necessary, via telephone 
completion or during clinic visits. Upon completion, data will be stored in a flow sheet format 
within Epic and a PRSM summary report will be generated for use at the next patient/provider 
visit. This electronic system will be developed and piloted during the first 5 months of the grant 
period and data collection will commence at month 6. Data collection will continue for 5 months, 
followed by data analysis and dissemination. 
Successful completion of this study will demonstrate the feasibility of utilizing an ePRO system 
that is directly linked to EPIC. We will leverage the results of this study to submit a National 
Institutes of Health (NIH) or Patient-Centered Outcomes Research Institute (PCORI) grant 
proposal to more fully test and evaluate this system in our Cancer Centers. We hope to then 
extend this ePRO system to obtain funding to develop a clinical decision support (CDS) tool to 
assure patients receive the best practices available to alleviate their symptom burden. 
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